PRME
Price
$1.23
Change
-$0.01 (-0.81%)
Updated
Apr 17, 04:59 PM (EDT)
Capitalization
162.64M
21 days until earnings call
RGLS
Price
$2.06
Change
+$0.12 (+6.19%)
Updated
Apr 17, 04:59 PM (EDT)
Capitalization
136.46M
20 days until earnings call
Ad is loading...

PRME vs RGLS

Header iconPRME vs RGLS Comparison
Open Charts PRME vs RGLSBanner chart's image
Prime Medicine
Price$1.23
Change-$0.01 (-0.81%)
Volume$3.72K
Capitalization162.64M
Regulus Therapeutics
Price$2.06
Change+$0.12 (+6.19%)
Volume$30.28K
Capitalization136.46M
PRME vs RGLS Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. RGLS commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and RGLS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (PRME: $1.24 vs. RGLS: $2.06)
Brand notoriety: PRME and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 32% vs. RGLS: 107%
Market capitalization -- PRME: $162.64M vs. RGLS: $136.46M
PRME [@Biotechnology] is valued at $162.64M. RGLS’s [@Biotechnology] market capitalization is $136.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileRGLS’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • RGLS’s FA Score: 0 green, 5 red.
According to our system of comparison, RGLS is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while RGLS’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 4 bearish.
  • RGLS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both PRME and RGLS are a good buy in the short-term.

Price Growth

PRME (@Biotechnology) experienced а +5.98% price change this week, while RGLS (@Biotechnology) price change was +19.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

PRME is expected to report earnings on May 09, 2025.

RGLS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($163M) has a higher market cap than RGLS($136M). RGLS YTD gains are higher at: 22.785 vs. PRME (-57.534). RGLS has higher annual earnings (EBITDA): -45.85M vs. PRME (-196.34M). PRME has more cash in the bank: 190M vs. RGLS (75.8M). RGLS has less debt than PRME: RGLS (274K) vs PRME (40.8M). PRME has higher revenues than RGLS: PRME (2.98M) vs RGLS (0).
PRMERGLSPRME / RGLS
Capitalization163M136M120%
EBITDA-196.34M-45.85M428%
Gain YTD-57.53422.785-253%
P/E RatioN/AN/A-
Revenue2.98M0-
Total Cash190M75.8M251%
Total Debt40.8M274K14,891%
FUNDAMENTALS RATINGS
PRME vs RGLS: Fundamental Ratings
PRME
RGLS
OUTLOOK RATING
1..100
7930
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
9537
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
58n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGLS's Valuation (32) in the Pharmaceuticals Other industry is in the same range as PRME (39) in the null industry. This means that RGLS’s stock grew similarly to PRME’s over the last 12 months.

RGLS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as PRME (100) in the null industry. This means that RGLS’s stock grew similarly to PRME’s over the last 12 months.

RGLS's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as PRME (96) in the null industry. This means that RGLS’s stock grew similarly to PRME’s over the last 12 months.

RGLS's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for PRME (95) in the null industry. This means that RGLS’s stock grew somewhat faster than PRME’s over the last 12 months.

RGLS's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as PRME (100) in the null industry. This means that RGLS’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMERGLS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 29 days ago
78%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ULPIX111.19N/A
N/A
ProFunds UltraBull Inv
PSSJX19.61N/A
N/A
Principal SmallCap S&P 600 Index J
FIQAX15.08N/A
N/A
Fidelity Advisor Asset Manager 60% Z
HSISX9.97N/A
N/A
Hartford Schroders Sust Intl Core I
PWETX13.13N/A
N/A
PACE International Em Mkts Eq P2

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-6.06%
CRSP - PRME
63%
Loosely correlated
-3.00%
RXRX - PRME
60%
Loosely correlated
-5.67%
BEAM - PRME
58%
Loosely correlated
-3.82%
NTLA - PRME
57%
Loosely correlated
-6.79%
ABCL - PRME
54%
Loosely correlated
-1.65%
More

RGLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGLS has been loosely correlated with NKTX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if RGLS jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
-0.51%
NKTX - RGLS
38%
Loosely correlated
+2.34%
KYMR - RGLS
33%
Poorly correlated
-1.73%
IMNM - RGLS
33%
Poorly correlated
-3.11%
LENZ - RGLS
32%
Poorly correlated
-3.47%
TRDA - RGLS
32%
Poorly correlated
-0.13%
More